| Literature DB >> 33747362 |
Julie Guibon1,2, Pierre-Emmanuel Sugier1, Om Kulkarni3, Mojgan Karimi1, Delphine Bacq-Daian3, Céline Besse3, Anne Boland3, Elisabeth Adjadj4, Frédérique Rachédi5, Carole Rubino4, Constance Xhaard4,6, Claire Mulot7, Pierre Laurent-Puig7, Anne-Valérie Guizard8,9, Claire Schvartz10, Rosa Maria Ortiz11, Yan Ren4, Evgenia Ostroumova12, Jean-François Deleuze3, Marie-Christine Boutron-Ruault1, Ausrele Kesminiene12, Florent De Vathaire4, Pascal Guénel1, Fabienne Lesueur2,13, Thérèse Truong1,13.
Abstract
Differentiated thyroid carcinoma (DTC) incidence is characterized by wide ethnic and geographic variations, with high incidence rates observed in Oceanian populations. Genome-wide association studies (GWAS) identified mainly four DTC susceptibility loci at 9q22.33, 14q13.3, 2q35 and 8p12. Here we performed fine-mapping of the 2q35 and 8p12 loci in the population of the EPITHYR consortium that includes Europeans, Melanesians and Polynesians to identify likely causal variants for DTC risk. We conducted a colocalization analysis using eQTLs data to determine the SNPs with the highest probability of causality. At 2q35, we highlighted rs16857609 located in DIRC3. This SNP has a high probability of causality in the three populations, and a significant association in Europeans (OR = 1.4, p = 1.9 x 10-10). It is also associated with expression of DIRC3 and of the nearby gene IGFBP5 in thyroid tumour cells. At 8p12, we identified rs7844425 which was significantly associated with DTC in Europeans (OR = 1.32, p = 7.6 x 10-8) and rs2439304, which was highlighted by the colocalization analysis but only moderately associated with DTC in our dataset (OR = 1.2, p = 0.001). These SNPs are linked to the expression of NRG1 in thyroid tissue. Hence, our study identified novel variants at 2q35 and 8p12 to be prioritized for further functional studies. Copyright:Entities:
Keywords: cancer genetics; case-control study; fine-mapping study; single nucleotide polymorphism; thyroid cancer
Year: 2021 PMID: 33747362 PMCID: PMC7939525 DOI: 10.18632/oncotarget.27888
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553